AstraZeneca PLC Looks for New Heart Drug Approval by Next May
Published: Sep 18, 2013
U.S. regulators have accepted an experimental fish oil-based heart drug from AstraZeneca for review and will make a decision on whether to approve it by next May. Epanova, for treating people with very high levels of fatty triglycerides in their blood, was developed by Omthera Pharmaceuticals, which AstraZeneca acquired earlier this year. AstraZeneca said on Wednesday that the U.S. Food and Drug Administration had set a date of May 5, 2014 to act on the Epanova submission.
Help employers find you! Check out all the jobs and post your resume.